The ANCOVA analysis of data from the full analysis population (i.e., all patients treated with eptinezumab, including 30, 100, and 300 mg) showed a highly comparable reduction in frequency of migraine days for the weeks 1–12 and weeks 13–24 treatment periods (Table 6), as well for the overall weeks 1–24 treatment period, for the ADA-positive vs ADA-negative subpopulations. Here, ADA is linked to migraine disorder.